Skip to main content
SpringerLink
Log in

Total neoadjuvant therapy in rectal cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Total neoadjuvant therapy is a novel approach for locally advanced rectal cancer. The optimal treatment sequence is, however, a matter of debate and until now, no overall survival benefit has been reported. This review is a critical, objective summary viewed from different perspectives of the available literature of previous milestones that have been achieved in the treatment of locally advanced rectal cancer, of current recommendations, and of future perspectives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Enker WE, Laffer UT, Block GE. Enhanced survival of patients with colon and rectal cancer is based upon wide anatomic resection. Ann Surg. 1979;190(3):350–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Pollett WG, Nicholls RJ. The relationship between the extent of distal clearance and survival and local recurrence rates after curative anterior resection for carcinoma of the rectum. Ann Surg. 1983;198(2):159–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don’t know. JAMA. 1988;259(24):3571–8.

    Article  CAS  PubMed  Google Scholar 

  4. Heald RJT. “Holy Plane” of rectal surgery. J R Soc Med. 1988;81(9):503–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cedermark B, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980–7.

    Article  CAS  PubMed  Google Scholar 

  6. Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.

    Article  CAS  PubMed  Google Scholar 

  7. Kapiteijn E, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.

    Article  CAS  PubMed  Google Scholar 

  8. Brown G, et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer. 2004;91(1):23–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Brown G. Local radiological staging of rectal cancer. Clin Radiol. 2004;59(3):213–4.

    Article  CAS  PubMed  Google Scholar 

  10. Beets-Tan RG, Beets GL. Local staging of rectal cancer: a review of imaging. J Magn Reson Imaging. 2011;33(5):1012–9.

    Article  PubMed  Google Scholar 

  11. Beets-Tan RG. MRI in rectal cancer: the T stage and circumferential resection margin. Colorectal Dis. 2003;5(5):392–5.

    Article  CAS  PubMed  Google Scholar 

  12. Maughan NJ, Quirke P. Modern management of colorectal cancer—a pathologist’s view. Scand J Surg. 2003;92(1):11–9.

    Article  CAS  PubMed  Google Scholar 

  13. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12.

    Article  PubMed  Google Scholar 

  14. Nagtegaal ID, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol. 2005;23(36):9257–64.

    Article  PubMed  Google Scholar 

  15. Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol. 2003;4(11):695–702.

    Article  PubMed  Google Scholar 

  16. van den Broek CB, et al. Differences in pre-operative treatment for rectal cancer between Norway, Sweden, Denmark, Belgium and the Netherlands. Eur J Surg Oncol. 2014;40(12):1789–96.

    Article  PubMed  Google Scholar 

  17. van Gijn W, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.

    Article  PubMed  Google Scholar 

  18. Breugom AJ, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200–7.

    Article  CAS  PubMed  Google Scholar 

  19. Bosset J‑F, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–90.

    Article  CAS  PubMed  Google Scholar 

  20. Schmoll HJ, et al. Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol. 2021;39(1):17–29.

    Article  CAS  PubMed  Google Scholar 

  21. Rödel C, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679–87.

    Article  PubMed  Google Scholar 

  22. Kim TW, et al. Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys. 2011;81(4):1025–31.

    Article  PubMed  Google Scholar 

  23. Marijnen CA, et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55(5):1311–20.

    Article  CAS  PubMed  Google Scholar 

  24. Strassburg J, et al. MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study. Ann Surg Oncol. 2011;18(10):2790–9.

    Article  PubMed  Google Scholar 

  25. Junginger T, et al. Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication. Zentralbl Chir. 2006;131(4):275–84.

    Article  PubMed  Google Scholar 

  26. Kreis ME, et al. Use of preoperative magnetic resonance imaging to select patients with rectal cancer for neoadjuvant chemoradiation—interim analysis of the German OCUM trial (NCT01325649). J Gastrointest Surg. 2016;20(1):25–32. discussion 32–33.

    Article  PubMed  Google Scholar 

  27. Ruppert R, et al. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM rectal cancer trial. Br J Surg. 2018;105(11):1519–29.

    Article  CAS  PubMed  Google Scholar 

  28. Ruppert R, et al. Avoidance of overtreatment of rectal cancer by selective chemoradiotherapy: results of the optimized surgery and MRI-based multimodal therapy trial. J Am Coll Surg. 2020;231(4):413–425.e2.

    Article  PubMed  Google Scholar 

  29. Maas M, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.

    Article  PubMed  Google Scholar 

  30. Petrelli F, et al. Pathologic complete response and disease-free survival are not surrogate endpoints for 5‑year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol. 2017;8(1):39–48.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sargent D, et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X‑ACT, PETACC‑3, C‑06, C‑07 and C89803. Eur J Cancer. 2011;47(7):990–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Merkel S, et al. Time to locoregional recurrence after curative resection of rectal carcinoma is prolonged after neoadjuvant treatment: a systematic review and meta-analysis. Colorectal Dis. 2011;13(2):123–31.

    Article  CAS  PubMed  Google Scholar 

  33. Allegra CJ, et al. Neoadjuvant 5‑FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107(11):djv248. https://doi.org/10.1093/jnci/djv248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Aschele C, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.

    Article  CAS  PubMed  Google Scholar 

  35. Deng HY, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. Eur J Cardiothorac Surg. 2017;51(3):421–31.

    PubMed  Google Scholar 

  36. Wiśniowska K, et al. Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study. Eur J Surg Oncol. 2016;42(12):1859–65.

    Article  PubMed  Google Scholar 

  37. Gerard JP, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638–44.

    Article  CAS  PubMed  Google Scholar 

  38. Rödel C, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89.

    Article  PubMed  Google Scholar 

  39. Bittner R, et al. Report on the workshop “workflow rectal cancer II” in Burghausen. Zentralbl Chir. 2007;132(2):95–8.

    Article  CAS  PubMed  Google Scholar 

  40. Buhr HJ, et al. Clinical pathway (workflow) for diagnostic, therapy and follow-up in patients with rectal cancer. Zentralbl Chir. 2006;131(4):285–97.

    Article  CAS  PubMed  Google Scholar 

  41. Roxburgh CSD, et al. Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short-term outcomes. Colorectal Dis. 2019;21(10):1140–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Conroy T, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–15.

    Article  CAS  PubMed  Google Scholar 

  43. Bahadoer RR, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42.

    Article  CAS  PubMed  Google Scholar 

  44. Garcia-Aguilar J, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546–56.

    Article  CAS  PubMed  Google Scholar 

  45. Fokas E, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8(1):e215445.

    Article  PubMed  Google Scholar 

  46. Jin J, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022; https://doi.org/10.1200/JCO.21.01667.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Benson AB, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(7):874–901.

    Article  PubMed  Google Scholar 

  48. Cercek A, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4(6):e180071.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Smith JJ, et al. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3‑year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Ludmir EB, et al. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017;123(9):1497–506.

    Article  PubMed  Google Scholar 

  51. Wang X, et al. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: a phase 2 trial. Radiother Oncol. 2018;129(2):300–5.

    Article  PubMed  Google Scholar 

  52. Riesco-Martinez MC, et al. Impact of total neoadjuvant therapy vs. standard chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis of randomized trials. Cancers (Basel). 2020;12(12):3655.

    Article  CAS  PubMed  Google Scholar 

  53. Liu S, et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist. 2021;26(9):e1555–e66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Valadão M, et al. Do we have to treat all T3 rectal cancer the same way? Clin Colorectal Cancer. 2020;19(4):231–5.

    Article  PubMed  Google Scholar 

  55. Lee JB, et al. Role of preoperative chemoradiotherapy in clinical stage II/III rectal cancer patients undergoing total mesorectal excision: a retrospective propensity score analysis. Front Oncol. 2020;10:609313.

    Article  PubMed  Google Scholar 

  56. Bujko K, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834–42.

    Article  CAS  PubMed  Google Scholar 

  57. Ciseł B, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298–303.

    Article  PubMed  Google Scholar 

  58. Benson AB, et al. NCCN guidelines insights: rectal cancer, version 6.2020. J Natl Compr Canc Netw. 2020;18(7):806–15.

    Article  PubMed  Google Scholar 

  59. Harrison JD, et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg. 2008;143(4):389–94.

    Article  PubMed  Google Scholar 

  60. Breugom AJ, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696–701.

    Article  CAS  PubMed  Google Scholar 

  61. Goodman KA. Definitive chemoradiotherapy (“watch-and-wait” approach). Semin Radiat Oncol. 2016;26(3):205–10.

    Article  PubMed  Google Scholar 

  62. Lopez-Campos F, et al. Watch and wait approach in rectal cancer: current controversies and future directions. World J Gastroenterol. 2020;26(29):4218–39.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Xu Q, et al. MRI evaluation of complete response of locally advanced rectal cancer after neoadjuvant therapy: current status and future trends. Cancer Manag Res. 2021;13:4317–28.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Dattani M, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268(6):955–67.

    Article  PubMed  Google Scholar 

  65. Habr-Gama A, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7. discussion 717–8.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Habr-Gama A, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53(12):1692–8.

    Article  PubMed  Google Scholar 

  67. Glynne-Jones R, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–iv40.

    Article  CAS  PubMed  Google Scholar 

  68. Yu M, et al. Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses. Int J Colorectal Dis. 2022;37(4):855–68.

    Article  PubMed  Google Scholar 

  69. Petrelli F, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263(3):458–64.

    Article  PubMed  Google Scholar 

  70. Deidda S, et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative Chemoradiation. JAMA Surg. 2021;156(12):1141–9.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Dizdarevic E, Hansen TF, Jakobsen A. The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal. Cancers (Basel). 2022;14(9):2252.

    Article  CAS  PubMed  Google Scholar 

  72. Murahashi S, et al. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer. 2020;123(5):803–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Vidal J, et al. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trial. Clin Cancer Res. 2021;27(10):2890–8.

    Article  CAS  PubMed  Google Scholar 

  74. Kotaka M, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. J Clin Oncol. 2022;40(4_suppl):9.

    Article  Google Scholar 

  75. Bach SP, et al. STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer? J Clin Oncol. 2022;40(16_suppl):3502–3502.

    Article  Google Scholar 

  76. Hearn N, et al. Neoadjuvant radiotherapy dose escalation in locally advanced rectal cancer: a systematic review and meta-analysis of modern treatment approaches and outcomes. Clin Oncol. 2021;33(1):e1–e14.

    Article  CAS  Google Scholar 

  77. Cercek A, et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res. 2020;26:3271–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.

    Article  PubMed  Google Scholar 

  79. Overmann MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.

    Article  Google Scholar 

  80. Cercek A, et al. PD‑1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Eng J Med. 2022;386:2363–76.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Med Campus III, Kepler University Hospital, Krankenhausstraße 9, 4020, Linz, Austria

    Gudrun Piringer MSc

  2. Department of Radiooncology, Hospital Feldkirch, Carinagasse 47, 6807, Feldkirch, Austria

    Alexander De Vries

Authors
  1. Gudrun Piringer MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander De Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander De Vries.

Ethics declarations

Conflict of interest

G. Piringer and A. De Vries declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piringer, G., De Vries, A. Total neoadjuvant therapy in rectal cancer. memo 16, 21–30 (2023). https://doi.org/10.1007/s12254-022-00854-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-022-00854-1

Keywords

Search

Navigation